<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02316028</url>
  </required_header>
  <id_info>
    <org_study_id>UZB-BN-2013-002</org_study_id>
    <nct_id>NCT02316028</nct_id>
  </id_info>
  <brief_title>Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC)</brief_title>
  <acronym>DECIT</acronym>
  <official_title>A Phase I Clinical Trial on Decitabine (5-aza-2'-Deoxycytidine) Administered by Hepatic Arterial Infusion in Patients With Unresectable Liver-predominant Metastases From Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite the advances in the medical treatment of unresectable liver metastases from&#xD;
      colorectal cancer there is currently no curative treatment option available for these&#xD;
      patients. Decitabine is a cytidine analog with proven anti-neoplastic activity in patients&#xD;
      with acute myeloid leukemia and myelodysplastic syndromes. Decitabine causes demethylation of&#xD;
      the DNA strands of replicating cells. Hereby decitabine treatment demethylates the promoter&#xD;
      regions of tumor suppressor- and cancer testis antigen encoding genes leading to expression&#xD;
      of these genes by the cancer cells. The hepatic arterial route for administration of&#xD;
      cytotoxic drugs has been widely explored in treatment of colorectal cancer liver metastases&#xD;
      because these metastases depend for their blood flow from this artery (as opposed to the&#xD;
      normal liver tissue that is mainly dependent from the portal vein). By investigating the&#xD;
      administration of decitabine by hepatic arterial infusion the investigators intend to explore&#xD;
      the potential advantage of minimizing the systemic exposure (and toxicity) and maximizing the&#xD;
      concentration of decitabine within the liver metastasis. The primary objective of this phase&#xD;
      I will be to establish the recommended dose for decitabine by HAI for further use in phase II&#xD;
      trials. The most important secondary objective will be to document the effect of decitabine&#xD;
      by HAI on the expression of cancer testis antigens by the colorectal cancer cells, serving as&#xD;
      a reference for potential further exploration of decitabine by HAI in combination with cancer&#xD;
      immunotherapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial will recruit eligible patients diagnosed with unresectable&#xD;
      liver-predominant colorectal cancer metastases who have experience progression of their&#xD;
      disease following standard of care treatment.&#xD;
&#xD;
      Unless patients already dispose of a hepatic arterial catheter, they will undergo placement&#xD;
      of a permanent hepatic artery catheter (by laparoscopic surgery). During this surgical&#xD;
      procedure a biopsy will be made of the colorectal cancer liver metastasis.&#xD;
&#xD;
      Decitabine will be administered as a daily 1-hour IV infusion on 5 consecutive days, every&#xD;
      4weeks.&#xD;
&#xD;
      Two weeks after the first day of administration of decitabine, a CT-guided biopsy a liver&#xD;
      metastasis will be performed in order to obtain tumor tissue for histopathological analysis&#xD;
      and DNA/RNA extraction for the purposes of methylation specific Polymerase Chain Reaction&#xD;
      (PCR) and reverse transcriptase PCR for assessment of demethylation and expression of&#xD;
      cancer-testis antigen encoding genes.&#xD;
&#xD;
      Blood samples for collection of &quot;cell-free DNA&quot; and White Blood Cell (WBC ) for the purpose&#xD;
      of DNA/RNA extraction and analysis by methylation specific PCR and reverse transcriptase PCR&#xD;
      for assessment of demethylation and expression of cancer-testis antigen encoding genes will&#xD;
      be obtained weekly after decitabine treatment.&#xD;
&#xD;
      The dose of decitabine will be escalated in subsequent patient cohorts enrolled to this phase&#xD;
      I trial (see rules for dose escalation).&#xD;
&#xD;
      Study treatment will be continued until unacceptable toxicity, progressive disease or patient&#xD;
      refusal.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>toxicity of escalating doses of decitabine administered by HAI</measure>
    <time_frame>2years</time_frame>
    <description>: to establish the recommended dose of decitabine administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases from colorectal cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5years</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>5 years</time_frame>
    <description>progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>best objective tumor response</measure>
    <time_frame>5 years</time_frame>
    <description>Best objective tumor response (BOR) per Response Evaluation Criteria in Solid Tumors (RECIST ), version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measuring Global DNA methylation of tumoral DNA</measure>
    <time_frame>2years</time_frame>
    <description>Determine the methylation status of the promoter region and messenger ribonucleic acid (mRNA) expression of cancer-testis antigens in pré- and post treatment biopsies of colorectal cancer liver metastases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measuring Global DNA methylation of cell free DNA</measure>
    <time_frame>2years</time_frame>
    <description>Determine the ratio of demethylated versus methylated DNA corresponding to the promoter region of cancer-testis antigen encoding genes on the circulating free DNA (cfDNA) in venous blood prior to and following the administration of decitabine by HAI</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Liver Metastasis</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>decitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>administration of decitabine by hepatic arterial infusion&#xD;
Accrual of patients and dosing of decitabine will be guided by a traditional 3+3 design using an accelerated titration for the first three dose levels.&#xD;
Proposed dose levels:&#xD;
10 mg/m2 per course&#xD;
15 mg/m2 per course&#xD;
20 mg/m2 per course</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>administration of decitabine by hepatic arterial infusion&#xD;
Accrual of patients and dosing of decitabine will be guided by a traditional 3+3 design using an accelerated titration for the first three dose levels.&#xD;
Proposed dose levels:&#xD;
10 mg/m2 per course&#xD;
15 mg/m2 per course&#xD;
20 mg/m2 per course</description>
    <arm_group_label>decitabine</arm_group_label>
    <other_name>Dacogen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological documentation of colorectal adenocarcinoma CRC stage IV with predominant&#xD;
             unresectable liver metastases and at least one measurable metastatic liver lesion&#xD;
&#xD;
          -  Performance status WHO criteria of &lt; 2.&#xD;
&#xD;
          -  Laboratory values: absolute neutrophil count (ANC) count &gt; 1500 /mm³, Platelet count &gt;&#xD;
             100 000 /mm³, Lymphocytes &gt; 800 /mm³, Serum creatinine &lt; 2.0 mg/dl or creatinine&#xD;
             clearance &gt;40 ml/min, Serum bilirubin &lt; 2.0 mg/dl&#xD;
&#xD;
          -  Progressive disease following standard of care palliative systemic chemotherapy&#xD;
&#xD;
          -  able to give written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No prior radiotherapy to all target liver lesions&#xD;
&#xD;
          -  No previous history of gastric or hepatobiliary surgery (except for simple&#xD;
             cholecystectomy, No concurrent liver disease or other serious medical disease or&#xD;
             condition&#xD;
&#xD;
          -  No concomitant use of other investigational drugs.&#xD;
&#xD;
          -  No pre-existing neuropathy with a severity of &gt; grade 1 in the WHO toxicity scale.&#xD;
&#xD;
          -  No previous or concurrent malignancies except for adequately treated in situ carcinoma&#xD;
             of the cervix uteri, basal or squamous cell carcinoma of the skin or any other&#xD;
             malignancy given potentially curative treatment more than 5 years before study entry&#xD;
&#xD;
          -  No pregnant or breast-feeding female patients, use of an effective contraceptive if&#xD;
             the risk of conception exists during study treatment.&#xD;
&#xD;
          -  No candidate for the resection of all CRC metastases with curative intent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bart Neyns, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Jette</city>
        <state>Brabant</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>December 3, 2014</study_first_submitted>
  <study_first_submitted_qc>December 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2014</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>decitabine</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>hepatic arterial infusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

